Diligence memo · auto-generated · as of July 2, 2026
Zymeworks Inc.
Zymeworks Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Zymeworks Inc. operates in Biotechnology, based in Vancouver.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Zymeworks Inc. has raised $143M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $62M on 2016-01-07.
Most recent recorded round closed around 2016-01-07.
Valuation (modeled)modeled
Provath models Zymeworks Inc. at approximately $2.5B (range $190M–$6.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.23× the median modeled value of Series C Biotechnology companies in 2016–2018 (41 peers) — value vs value, same stage and era. Within the normal band (123% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 10.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 34.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Genesis Biopharma, Inc, Alder Biopharmaceuticals Inc, Ideaya Biosciences, Inc., Stoke Therapeutics, Inc., 4D Molecular Therapeutics Inc.
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.